Tech Company Financing Transactions
ViferaXS Funding Round
ViferaXS closed a $13.5 million Series A funding round on 9/23/2026. Backers included private investors.
Transaction Overview
Company Name
Announced On
9/23/2026
Transaction Type
Venture Equity
Amount
$13,500,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Karlstraße 3
Tübingen, 72072
Germany
Tübingen, 72072
Germany
Phone
Undisclosed
Website
Email Address
Overview
ViferaXS is a pioneering biotech company specializing in cancer immunotherapies based on peptide-based T cell activators that combine tumor-specific antigens with potent immune stimulation.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sezai Taskin
Co-Founder
Hans-Georg Rammensee
Co-Founder
Juliane Walz
Browse more venture capital transactions:
Prev: 9/23/2026: Palma.ai venture capital transaction
Next: 9/23/2026: Falcon Gases venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs